Physician profile
Dina Alayan
NPI 1083212765
$1,100.68
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $51.08 · 2021: $330 · 2022: $516 · 2023: $204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $203.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $203.45 | 2020-2023 | Recarbrio, Dificid, Zerbaxa |
| Janssen Pharmaceuticals, INC | $176.53 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.55 | 2021-2023 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $116.07 | 2021-2022 | |
| Gilead Sciences, INC. | $108.12 | 2022-2023 | |
| Alexion Pharmaceuticals, INC. | $90.52 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $84.04 | 2022 | |
| Insmed, INC. | $55.15 | 2022 | |
| Abbvie INC. | $48.28 | 2022-2023 | Avycaz |
| La Jolla Pharmaceutical Company | $22.96 | 2023 | Xerava |
| Aurinia Pharma U.S., INC. | $20.34 | 2023 | Lupkynis |
| Pfizer INC. | $16.67 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dina Alayan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.